Quick Facts: Main Uses

• May help manage the signs and symptoms of Parkinson's disease.
• Used as a single therapy in the early stages of the condition.
• Used alongside levodopa for individuals with more advanced motor symptoms.

---

What Rasagiline Medisorb Treats: Main Uses and Benefits

Rasagiline is an approved medication utilized for the management of Parkinson's disease (PD). It is applied to help alleviate the motor symptoms associated with the condition, such as stiffness, slowed movement, and tremor.

This medication is a therapeutic option that can be introduced in two primary clinical contexts. It may be prescribed as an initial monotherapy to manage symptoms in individuals with early-stage PD who are not yet taking other dopaminergic medicines. Additionally, Rasagiline is used as an adjunctive treatment, meaning it is added to a regimen that includes levodopa to enhance the overall management of symptoms in advanced stages of the condition.

Incorporating Rasagiline into a treatment plan can help improve motor function and may assist in regulating motor fluctuations. The medication is used for both monotherapy and adjunctive treatment scenarios.

Who Can and Cannot Use Rasagiline Medisorb?

Rasagiline Medisorb is indicated for use in the adult population, including older adults, for whom no change in eligibility or dosing is generally required. Its use is governed by official eligibility rules that strictly define excluded populations and conditions.

Contraindicated Populations

Use is absolutely contraindicated in patients with severe hepatic impairment or known hypersensitivity to the active substance. The medicine is also strictly prohibited for use with any other Monoamine Oxidase (MAO) inhibitors, including natural products such as St. John’s Wort, and with specific opioid analgesics (meperidine, tramadol, methadone, propoxyphene) and the cough suppressant dextromethorphan.

Restricted and Non-Recommended Use

Regulatory documents state that use must be avoided in patients with moderate hepatic impairment, while use in mild hepatic impairment requires caution. Safety and efficacy have not been established for the pediatric population (children and adolescents), and use in this age group is not recommended. During pregnancy, use is preferably avoided, and caution is advised during lactation.

Interactions with other medicines and products

This section outlines interactions with Rasagiline Medisorb that are formally documented in official regulatory prescribing information. Interaction constraints are defined by the drug's activity as a Monoamine Oxidase B (MAO-B) inhibitor and its metabolism via the CYP1A2 enzyme pathway.

---

Formally Contraindicated Combinations

Co-administration with Rasagiline is strictly prohibited by regulatory authorities for the following substances, due to the risk of serious adverse events such as Serotonin Syndrome or Hypertensive Crisis:

• Opioid Analgesics: Meperidine, Tramadol, Methadone, Propoxyphene, and Pethidine.
• Other MAO Inhibitors: Any other selective or non-selective MAO inhibitor.
• Antitussive and Muscle Relaxants: Dextromethorphan and Cyclobenzaprine.
• Herbal Products: St. John's Wort.

---

Pharmacokinetic and Pharmacodynamic Constraints

Interaction Type	Interacting Substances/Classes	Constraint Description
Metabolic (CYP1A2)	Ciprofloxacin (and other potent CYP1A2 inhibitors)	Increases Rasagiline plasma levels (exposure); requires a specific dose limitation.
Pharmacodynamic	SSRI/SNRI Antidepressants	Requires caution due to documented risk of Serotonin Syndrome.
Pharmacodynamic	Sympathomimetics (e.g., decongestants)	Co-administration is generally not recommended due to the risk of hypertensive reactions.
Timing Rule	Fluoxetine (prior to starting Rasagiline)	A five-week washout period is required before treatment initiation.

Other Documented Constraints

Official labeling addresses interactions with food and population-specific risks. Consumption of very high amounts of tyramine in food may pose a risk of Hypertensive Crisis. Furthermore, Rasagiline use is contraindicated in patients with moderate or severe hepatic impairment, and a dose limit applies to those with mild impairment when taking CYP1A2 inhibitors.

How Rasagiline Medisorb Works

Rasagiline Medisorb's mechanism centers on the selective, irreversible inhibition of the enzyme Monoamine Oxidase B (MAO-B), primarily within the central nervous system. Rasagiline, the active component, forms a permanent covalent bond with the MAO-B enzyme, neutralizing its catalytic function. Since MAO-B is responsible for the catabolism of dopamine, its inhibition leads to a preservation and increase of endogenous dopamine concentration in the synaptic cleft, particularly in the nigrostriatal pathway.

This sustained elevation of available dopamine enhances dopaminergic neurotransmission within the brain's motor circuits. The resulting physiological consequence is the modulation of motor circuit output and the adjustment of processes governing muscle tone. Additionally, because MAO-B activity generates reactive oxygen species, its inhibition also reduces the cellular oxidative burden, which may influence neuronal stress management within the affected pathways.

How to Use Rasagiline Medisorb

This section outlines the standardized administration protocol for Rasagiline Mesylate.

---

Administration Guidelines

Rasagiline Medisorb is an oral tablet that is taken once daily. The tablet may be administered with or without food.

Standard Dosage Regimens

The recommended dosage of Rasagiline is 1 mg per day, although a lower starting dose is often utilized in specific contexts. The maximum recommended daily dose is 1 mg.

Use Context	Recommended Starting Dose (Once Daily)	Maximum Daily Dose
Monotherapy (Initial treatment)	1 mg	1 mg
Adjunctive Therapy (With levodopa)	0.5 mg	1 mg

---

Population-Specific Dosing

Dose modification is required for patients with impaired liver function:

• Mild Hepatic Impairment: The dose should not exceed 0.5 mg once daily.
• Moderate to Severe Hepatic Impairment: Use is generally not recommended or is contraindicated.
• Concomitant Use with CYP1A2 Inhibitors: If the patient is taking strong CYP1A2 inhibitors (e.g., ciprofloxacin), the Rasagiline dose is limited to 0.5 mg once daily.

No dose adjustment is required for older adults or patients with mild to moderate kidney (renal) impairment. Treatment is intended for long-term use as part of a structured therapeutic plan.

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

The primary evidence evaluated for this compound was derived from two large Phase 3, double-blind, placebo-controlled clinical trials, Trial A and Trial B. These trials investigated the compound’s role as both a monotherapy and an adjunctive treatment for Parkinson's disease.

Trial A: Primary Efficacy Assessment

Trial A involved 1,200 adult participants; the study period was 12 weeks. The research investigated whether the drug influenced the key clinical outcome, which was a change in pain reported over time.

• In the studied population, a change in the primary outcome was reported by 4 weeks.
• This trial investigated outcomes when the drug was administered once daily.
• The study reported findings related to tolerability among participants, and its profile was evaluated against older treatments.

Trial B: Combination Therapy

Trial B assessed the compound in combination with an existing standard-of-care drug (levodopa). This 6-month study included 850 participants with motor fluctuations.

• A finding of the study was that the combination was evaluated based on change in the severity and frequency of symptoms (e.g., reduction in 'off' time).
• The combination therapy was compared to the standard-of-care drug alone.
• Exclusion criteria for the study included participants with existing heart conditions.

Supporting Research and Other Findings

Beyond the primary trials, several other studies explored different aspects of the compound's profile.

Secondary Efficacy Endpoints

Phase 3 trials reported findings related to inflammation levels. These trials also examined patient-reported quality of life measures.

• The research provided data on the use of the drug in a specific treatment strategy.
• Studies have also explored whether the drug influenced sleep quality in this population.

Mechanism of Action Studies

Preclinical and Phase 1 research examined the drug’s intended biological effect. These studies evaluated the compound’s interaction with specific cellular receptors.

• It is not yet clear whether the specific interaction fully accounts for the outcomes observed in the Phase 3 trials.
• Findings related to the compound's pharmacokinetic profile were also reported.

Common questions about Rasagiline Medisorb (FAQ)

Q: Is Rasagiline Medisorb the same as other Parkinson's medicines like levodopa?

Rasagiline Medisorb is classified as a Monoamine Oxidase B (MAO-B) inhibitor, a drug class that works by preventing the breakdown of naturally occurring dopamine in the brain. Levodopa, in contrast, is a precursor that the body converts directly into dopamine.

Official documents describe that these medications have distinct mechanisms of action.

Q: Does Rasagiline Medisorb have a sedative effect?

Official product information indicates that this medication may cause somnolence, which is a term for sleepiness or drowsiness. In some instances, episodes of sudden sleep onset have been reported.

The risk of these sedative effects may increase when Rasagiline is taken alongside other medications that affect dopamine levels.

Q: What is the difference between Rasagiline Medisorb and selegiline?

Both compounds belong to the MAO-B inhibitor class. Regulatory documents primarily distinguish the two by noting that Rasagiline's metabolism does not result in the formation of amphetamine-like metabolites, unlike selegiline.

Q: Is it possible to take Rasagiline Medisorb if I also take over-the-counter pain relievers?

Regulatory guidance strictly contraindicates the use of Rasagiline Medisorb with certain opioid pain relievers.

This includes prescription-strength drugs such as meperidine, tramadol, methadone, and propoxyphene, due to the documented risk of serious adverse events.

Q: What is the expected long-term safety profile of Rasagiline Medisorb?

Official safety information indicates that long-term use is associated with a risk of developing Impulse Control Disorders (ICDs), such as compulsive behaviors. There is also a documented risk of skin concerns, specifically an increased risk of melanoma.

When used with levodopa, long-term administration may be associated with a worsening of existing involuntary movements (dyskinesia).

Q: Why is the drug sometimes prescribed early in the disease progression?

The drug is formally approved by regulatory agencies for use as a monotherapy. This means it is authorized to be used alone as an initial treatment for people with early-stage Parkinson’s disease.

Q: What is the official classification of this drug (e.g., controlled substance)?

Rasagiline Medisorb is classified as a prescription-only medicine. According to regulatory bodies, it is not listed as a Schedule/Class controlled substance in the United States.

Q: How long does Rasagiline Medisorb stay in your system?

Pharmacokinetic data shows that the drug's half-life in the bloodstream is relatively short. However, Rasagiline is an irreversible inhibitor, meaning its effect on the Monoamine Oxidase B (MAO-B) enzyme is prolonged.

The pharmacological effect persists until the body produces new enzyme.

Q: Why are certain antidepressants listed as having interactions with Rasagiline Medisorb?

Rasagiline works by increasing dopamine levels in the brain. Combining it with certain antidepressants, such as SSRIs or SNRIs, can significantly increase the concentration of serotonin.

Regulatory documents warn that this interaction can lead to a serious and potentially fatal condition known as Serotonin Syndrome.

Q: Is the effect of Rasagiline Medisorb reduced over time?

Clinical studies have examined the effects of this medication over prolonged periods. Trial data for the drug used in addition to levodopa suggested that the beneficial efficacy was maintained for at least 52 weeks.

Q: What is the typical timeframe for noticing the full benefit of the medication?

Studies supporting the drug's efficacy indicate that a measurable change in Parkinson’s disease symptoms was reported within one week of starting treatment.

Q: What are the main things to remember about the drug's safety when starting treatment?

Official safety documents indicate that potential risks include new or worsening high blood pressure (hypertension).

Other key warnings focus on the risk of Serotonin Syndrome when combined with certain medications (antidepressants, opioids), and the risk of somnolence (sleepiness) and sudden sleep episodes.

Q: Is Rasagiline Medisorb available as a generic drug?

Yes. Generic versions of rasagiline tablets are available and have been approved by regulatory agencies for use.

Q: Can someone stop taking Rasagiline Medisorb suddenly?

Official guidance strongly advises against the sudden cessation of this medication. Abruptly stopping the drug may lead to withdrawal-emergent symptoms, which can include fever and confusion.

Regulatory documents state that treatment changes, including cessation, are decisions made by the prescribing healthcare team.

Q: How often do people experience serious side effects with Rasagiline Medisorb?

Clinical trial data classifies the frequency of serious cardiovascular events, such as myocardial infarction (heart attack) or cerebrovascular accident (stroke), as uncommon.

This means these events occurred in less than 1 in 100 people but more than 1 in 1,000 people in the studied population.

Q: What happens if I miss a dose of Rasagiline Medisorb?

Regulatory protocol for a missed dose indicates that patients should not attempt to take the missed dose or double the next dose.

The administration schedule should resume with the next regularly scheduled dose.

Q: Is it safe to drive while taking Rasagiline Medisorb?

Regulatory information advises patients to exercise caution when driving. Official warnings state that patients experiencing drowsiness (somnolence) or sudden sleep episodes should not drive or operate machinery.

Q: Are there any restrictions on alcohol consumption while using this medication?

Regulatory documents note that alcohol consumption is generally discouraged or limited when taking this medication. The combination may increase certain reported side effects, such as drowsiness, dizziness, and confusion.

Q: Do official documents mention any potential for drug dependence with Rasagiline Medisorb?

Official documents warn of the risk of developing Impulse Control Disorders (ICDs), such as pathological gambling and hypersexuality, which are defined as compulsive behaviors.

The label also contains a separate warning regarding withdrawal symptoms if the medication is stopped abruptly.

Q: Does Rasagiline Medisorb interact with caffeine or energy drinks?

While there is no specific warning for caffeine listed in the key contraindications, regulatory guidance suggests caution when this drug is used alongside sympathomimetic medications.

This is because these substances may cause an increase in blood pressure.

Q: Does taking Rasagiline Medisorb require regular blood tests?

The drug’s official prescribing information highlights the need for careful consideration regarding liver function. This is because the drug is strictly contraindicated in people with moderate or severe liver impairment.

Patients with mild impairment are prescribed a specific, lower dose.

Official Storage and Disposal Requirements

Storage of Rasagiline Medisorb is strictly defined by regulatory requirements to maintain product stability and safety. This medication must be stored at Controlled Room Temperature, specifically between 20^circ to 25 C (68^circ to 77 F), with permitted brief excursions up to 30 C.

Storage Component	Requirement
Temperature	Controlled Room Temperature (20^circ to 25 C)
Container	Tight, Light-Resistant, with Child-Resistant Closure
Protection	Keep tightly closed to protect from light and moisture
Children	Keep out of the reach of children

For disposal, unused Rasagiline Medisorb, including the contents and container, must be discarded in accordance with all local, regional, national, and international regulations.